nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—AOX1—Methotrexate—testicular cancer	0.184	0.311	CbGbCtD
Raloxifene—CYP2B6—Ifosfamide—testicular cancer	0.112	0.189	CbGbCtD
Raloxifene—CYP2C8—Ifosfamide—testicular cancer	0.085	0.143	CbGbCtD
Raloxifene—CYP2B6—Cisplatin—testicular cancer	0.0546	0.0919	CbGbCtD
Raloxifene—CYP2C8—Etoposide—testicular cancer	0.0406	0.0684	CbGbCtD
Raloxifene—CYP2B6—Doxorubicin—testicular cancer	0.0366	0.0616	CbGbCtD
Raloxifene—CYP3A4—Ifosfamide—testicular cancer	0.0345	0.058	CbGbCtD
Raloxifene—ESR2—seminiferous tubule of testis—testicular cancer	0.0342	0.217	CbGeAlD
Raloxifene—CYP19A1—corpus luteum—testicular cancer	0.0318	0.202	CbGeAlD
Raloxifene—CYP19A1—seminiferous tubule of testis—testicular cancer	0.0269	0.171	CbGeAlD
Raloxifene—CYP3A4—Vinblastine—testicular cancer	0.0183	0.0308	CbGbCtD
Raloxifene—CYP3A4—Etoposide—testicular cancer	0.0165	0.0277	CbGbCtD
Raloxifene—CYP19A1—semen—testicular cancer	0.0149	0.0945	CbGeAlD
Raloxifene—CYP3A4—Doxorubicin—testicular cancer	0.0112	0.0189	CbGbCtD
Raloxifene—ESR2—Ovarian Infertility Genes—DAZL—testicular cancer	0.00648	0.364	CbGpPWpGaD
Raloxifene—AOX1—seminal vesicle—testicular cancer	0.00385	0.0245	CbGeAlD
Raloxifene—CYP19A1—Ovarian Infertility Genes—DAZL—testicular cancer	0.00365	0.205	CbGpPWpGaD
Raloxifene—SIGMAR1—seminal vesicle—testicular cancer	0.0031	0.0197	CbGeAlD
Raloxifene—ESR1—embryo—testicular cancer	0.00292	0.0185	CbGeAlD
Raloxifene—ESR2—gonad—testicular cancer	0.00289	0.0184	CbGeAlD
Raloxifene—AOX1—gonad—testicular cancer	0.00278	0.0177	CbGeAlD
Raloxifene—ESR2—female gonad—testicular cancer	0.00235	0.0149	CbGeAlD
Raloxifene—CYP19A1—gonad—testicular cancer	0.00228	0.0145	CbGeAlD
Raloxifene—AOX1—female gonad—testicular cancer	0.00226	0.0144	CbGeAlD
Raloxifene—ESR2—testis—testicular cancer	0.00208	0.0132	CbGeAlD
Raloxifene—AOX1—testis—testicular cancer	0.00201	0.0127	CbGeAlD
Raloxifene—ESR1—gonad—testicular cancer	0.00198	0.0126	CbGeAlD
Raloxifene—CYP19A1—female gonad—testicular cancer	0.00185	0.0118	CbGeAlD
Raloxifene—SIGMAR1—female gonad—testicular cancer	0.00182	0.0116	CbGeAlD
Raloxifene—CYP19A1—testis—testicular cancer	0.00164	0.0104	CbGeAlD
Raloxifene—SIGMAR1—testis—testicular cancer	0.00162	0.0103	CbGeAlD
Raloxifene—ESR1—female gonad—testicular cancer	0.00161	0.0102	CbGeAlD
Raloxifene—ESR2—lymph node—testicular cancer	0.00151	0.0096	CbGeAlD
Raloxifene—CYP2B6—gonad—testicular cancer	0.00146	0.0093	CbGeAlD
Raloxifene—AOX1—lymph node—testicular cancer	0.00145	0.00924	CbGeAlD
Raloxifene—ESR1—testis—testicular cancer	0.00143	0.00907	CbGeAlD
Raloxifene—CYP19A1—lymph node—testicular cancer	0.00119	0.00757	CbGeAlD
Raloxifene—CYP2C8—testis—testicular cancer	0.00118	0.00747	CbGeAlD
Raloxifene—SIGMAR1—lymph node—testicular cancer	0.00117	0.00744	CbGeAlD
Raloxifene—HTR2B—lymph node—testicular cancer	0.00117	0.00742	CbGeAlD
Raloxifene—CYP2B6—testis—testicular cancer	0.00106	0.0067	CbGeAlD
Raloxifene—ESR1—lymph node—testicular cancer	0.00104	0.00658	CbGeAlD
Raloxifene—HTR6—G alpha (s) signalling events—INSL3—testicular cancer	0.000633	0.0356	CbGpPWpGaD
Raloxifene—Cystitis—Doxorubicin—testicular cancer	0.000596	0.00258	CcSEcCtD
Raloxifene—Diabetes mellitus—Methotrexate—testicular cancer	0.000595	0.00258	CcSEcCtD
Raloxifene—Hypoaesthesia—Etoposide—testicular cancer	0.000595	0.00257	CcSEcCtD
Raloxifene—Vertigo—Ifosfamide—testicular cancer	0.000592	0.00256	CcSEcCtD
Raloxifene—Urinary tract disorder—Etoposide—testicular cancer	0.00059	0.00256	CcSEcCtD
Raloxifene—Abdominal pain—Vinblastine—testicular cancer	0.000589	0.00255	CcSEcCtD
Raloxifene—Urethral disorder—Etoposide—testicular cancer	0.000586	0.00254	CcSEcCtD
Raloxifene—Infection—Dactinomycin—testicular cancer	0.000583	0.00252	CcSEcCtD
Raloxifene—Vaginal infection—Doxorubicin—testicular cancer	0.000583	0.00252	CcSEcCtD
Raloxifene—Cough—Ifosfamide—testicular cancer	0.000575	0.00249	CcSEcCtD
Raloxifene—Thrombocytopenia—Dactinomycin—testicular cancer	0.000574	0.00249	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.000573	0.00248	CcSEcCtD
Raloxifene—Cramps of lower extremities—Doxorubicin—testicular cancer	0.000567	0.00246	CcSEcCtD
Raloxifene—Myalgia—Ifosfamide—testicular cancer	0.000561	0.00243	CcSEcCtD
Raloxifene—Arthralgia—Ifosfamide—testicular cancer	0.000561	0.00243	CcSEcCtD
Raloxifene—Chest pain—Ifosfamide—testicular cancer	0.000561	0.00243	CcSEcCtD
Raloxifene—Flatulence—Cisplatin—testicular cancer	0.000559	0.00242	CcSEcCtD
Raloxifene—Bladder pain—Doxorubicin—testicular cancer	0.000558	0.00242	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.000557	0.00241	CcSEcCtD
Raloxifene—Diabetes mellitus—Epirubicin—testicular cancer	0.000557	0.00241	CcSEcCtD
Raloxifene—Diarrhoea—Chlorambucil—testicular cancer	0.000556	0.00241	CcSEcCtD
Raloxifene—Flushing—Etoposide—testicular cancer	0.000555	0.0024	CcSEcCtD
Raloxifene—Cardiac disorder—Etoposide—testicular cancer	0.000555	0.0024	CcSEcCtD
Raloxifene—Muscle spasms—Cisplatin—testicular cancer	0.000546	0.00236	CcSEcCtD
Raloxifene—Angiopathy—Etoposide—testicular cancer	0.000542	0.00235	CcSEcCtD
Raloxifene—Pain—Bleomycin—testicular cancer	0.000538	0.00233	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.000534	0.00231	CcSEcCtD
Raloxifene—Infection—Ifosfamide—testicular cancer	0.000534	0.00231	CcSEcCtD
Raloxifene—Cerebrovascular accident—Methotrexate—testicular cancer	0.000528	0.00229	CcSEcCtD
Raloxifene—Nervous system disorder—Ifosfamide—testicular cancer	0.000527	0.00228	CcSEcCtD
Raloxifene—Thrombocytopenia—Ifosfamide—testicular cancer	0.000526	0.00228	CcSEcCtD
Raloxifene—Skin disorder—Ifosfamide—testicular cancer	0.000522	0.00226	CcSEcCtD
Raloxifene—Hyperhidrosis—Ifosfamide—testicular cancer	0.00052	0.00225	CcSEcCtD
Raloxifene—Hot flush—Epirubicin—testicular cancer	0.000518	0.00224	CcSEcCtD
Raloxifene—Vomiting—Chlorambucil—testicular cancer	0.000517	0.00224	CcSEcCtD
Raloxifene—Diabetes mellitus—Doxorubicin—testicular cancer	0.000515	0.00223	CcSEcCtD
Raloxifene—Menopausal symptoms—Epirubicin—testicular cancer	0.000513	0.00222	CcSEcCtD
Raloxifene—Diarrhoea—Vinblastine—testicular cancer	0.000509	0.00221	CcSEcCtD
Raloxifene—Pain—Dactinomycin—testicular cancer	0.000502	0.00217	CcSEcCtD
Raloxifene—Muscle spasms—Etoposide—testicular cancer	0.0005	0.00217	CcSEcCtD
Raloxifene—Body temperature increased—Bleomycin—testicular cancer	0.000497	0.00215	CcSEcCtD
Raloxifene—Cerebrovascular accident—Epirubicin—testicular cancer	0.000494	0.00214	CcSEcCtD
Raloxifene—Dizziness—Vinblastine—testicular cancer	0.000492	0.00213	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.00049	0.00212	CcSEcCtD
Raloxifene—Myalgia—Cisplatin—testicular cancer	0.000483	0.00209	CcSEcCtD
Raloxifene—Nausea—Chlorambucil—testicular cancer	0.000483	0.00209	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00048	0.00208	CcSEcCtD
Raloxifene—Gastrointestinal pain—Dactinomycin—testicular cancer	0.00048	0.00208	CcSEcCtD
Raloxifene—Hot flush—Doxorubicin—testicular cancer	0.000479	0.00207	CcSEcCtD
Raloxifene—Migraine—Epirubicin—testicular cancer	0.000477	0.00206	CcSEcCtD
Raloxifene—Menopausal symptoms—Doxorubicin—testicular cancer	0.000475	0.00206	CcSEcCtD
Raloxifene—Vomiting—Vinblastine—testicular cancer	0.000473	0.00205	CcSEcCtD
Raloxifene—Breast disorder—Methotrexate—testicular cancer	0.000467	0.00202	CcSEcCtD
Raloxifene—Vertigo—Etoposide—testicular cancer	0.000467	0.00202	CcSEcCtD
Raloxifene—Headache—Vinblastine—testicular cancer	0.000466	0.00202	CcSEcCtD
Raloxifene—ESR1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000466	0.0262	CbGpPWpGaD
Raloxifene—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000464	0.00201	CcSEcCtD
Raloxifene—Body temperature increased—Dactinomycin—testicular cancer	0.000464	0.00201	CcSEcCtD
Raloxifene—Abdominal pain—Dactinomycin—testicular cancer	0.000464	0.00201	CcSEcCtD
Raloxifene—Infection—Cisplatin—testicular cancer	0.00046	0.00199	CcSEcCtD
Raloxifene—Pain—Ifosfamide—testicular cancer	0.00046	0.00199	CcSEcCtD
Raloxifene—Loss of consciousness—Etoposide—testicular cancer	0.000457	0.00198	CcSEcCtD
Raloxifene—Cerebrovascular accident—Doxorubicin—testicular cancer	0.000457	0.00198	CcSEcCtD
Raloxifene—Nervous system disorder—Cisplatin—testicular cancer	0.000454	0.00197	CcSEcCtD
Raloxifene—Cough—Etoposide—testicular cancer	0.000454	0.00197	CcSEcCtD
Raloxifene—Thrombocytopenia—Cisplatin—testicular cancer	0.000454	0.00196	CcSEcCtD
Raloxifene—Skin disorder—Cisplatin—testicular cancer	0.00045	0.00195	CcSEcCtD
Raloxifene—Hyperhidrosis—Cisplatin—testicular cancer	0.000448	0.00194	CcSEcCtD
Raloxifene—Chest pain—Etoposide—testicular cancer	0.000443	0.00192	CcSEcCtD
Raloxifene—Nausea—Vinblastine—testicular cancer	0.000442	0.00192	CcSEcCtD
Raloxifene—Migraine—Doxorubicin—testicular cancer	0.000441	0.00191	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00044	0.0019	CcSEcCtD
Raloxifene—Gastrointestinal pain—Ifosfamide—testicular cancer	0.00044	0.0019	CcSEcCtD
Raloxifene—Breast disorder—Epirubicin—testicular cancer	0.000438	0.00189	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.000436	0.00189	CcSEcCtD
Raloxifene—Abdominal pain—Ifosfamide—testicular cancer	0.000425	0.00184	CcSEcCtD
Raloxifene—Body temperature increased—Ifosfamide—testicular cancer	0.000425	0.00184	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000422	0.00183	CcSEcCtD
Raloxifene—Infection—Etoposide—testicular cancer	0.000422	0.00183	CcSEcCtD
Raloxifene—Influenza—Epirubicin—testicular cancer	0.000418	0.00181	CcSEcCtD
Raloxifene—Thrombocytopenia—Etoposide—testicular cancer	0.000416	0.0018	CcSEcCtD
Raloxifene—Skin disorder—Etoposide—testicular cancer	0.000412	0.00179	CcSEcCtD
Raloxifene—ESR2—Plasma membrane estrogen receptor signaling—MMP2—testicular cancer	0.000412	0.0232	CbGpPWpGaD
Raloxifene—Hyperhidrosis—Etoposide—testicular cancer	0.00041	0.00178	CcSEcCtD
Raloxifene—Breast disorder—Doxorubicin—testicular cancer	0.000405	0.00175	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000403	0.00175	CcSEcCtD
Raloxifene—Bronchitis—Epirubicin—testicular cancer	0.000402	0.00174	CcSEcCtD
Raloxifene—Diarrhoea—Dactinomycin—testicular cancer	0.000401	0.00174	CcSEcCtD
Raloxifene—Pneumonia—Methotrexate—testicular cancer	0.000401	0.00174	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Cisplatin—testicular cancer	0.0004	0.00173	CcSEcCtD
Raloxifene—Vomiting—Bleomycin—testicular cancer	0.0004	0.00173	CcSEcCtD
Raloxifene—Depression—Methotrexate—testicular cancer	0.000398	0.00172	CcSEcCtD
Raloxifene—Rash—Bleomycin—testicular cancer	0.000397	0.00172	CcSEcCtD
Raloxifene—Pain—Cisplatin—testicular cancer	0.000396	0.00172	CcSEcCtD
Raloxifene—Dermatitis—Bleomycin—testicular cancer	0.000396	0.00172	CcSEcCtD
Raloxifene—Conjunctivitis—Methotrexate—testicular cancer	0.000388	0.00168	CcSEcCtD
Raloxifene—Influenza—Doxorubicin—testicular cancer	0.000387	0.00168	CcSEcCtD
Raloxifene—Sweating—Methotrexate—testicular cancer	0.000382	0.00166	CcSEcCtD
Raloxifene—Weight increased—Epirubicin—testicular cancer	0.000381	0.00165	CcSEcCtD
Raloxifene—Pneumonia—Epirubicin—testicular cancer	0.000375	0.00163	CcSEcCtD
Raloxifene—Nausea—Bleomycin—testicular cancer	0.000374	0.00162	CcSEcCtD
Raloxifene—Vomiting—Dactinomycin—testicular cancer	0.000373	0.00161	CcSEcCtD
Raloxifene—Bronchitis—Doxorubicin—testicular cancer	0.000372	0.00161	CcSEcCtD
Raloxifene—Rash—Dactinomycin—testicular cancer	0.00037	0.0016	CcSEcCtD
Raloxifene—Diarrhoea—Ifosfamide—testicular cancer	0.000368	0.00159	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Etoposide—testicular cancer	0.000366	0.00159	CcSEcCtD
Raloxifene—Body temperature increased—Cisplatin—testicular cancer	0.000366	0.00159	CcSEcCtD
Raloxifene—Pain—Etoposide—testicular cancer	0.000363	0.00157	CcSEcCtD
Raloxifene—Conjunctivitis—Epirubicin—testicular cancer	0.000363	0.00157	CcSEcCtD
Raloxifene—Urinary tract infection—Epirubicin—testicular cancer	0.000363	0.00157	CcSEcCtD
Raloxifene—Sweating—Epirubicin—testicular cancer	0.000358	0.00155	CcSEcCtD
Raloxifene—ESR1—LKB1 signaling events—STK11—testicular cancer	0.000358	0.0201	CbGpPWpGaD
Raloxifene—Dizziness—Ifosfamide—testicular cancer	0.000355	0.00154	CcSEcCtD
Raloxifene—Pharyngitis—Methotrexate—testicular cancer	0.000355	0.00154	CcSEcCtD
Raloxifene—Urinary tract disorder—Methotrexate—testicular cancer	0.000353	0.00153	CcSEcCtD
Raloxifene—Weight increased—Doxorubicin—testicular cancer	0.000352	0.00153	CcSEcCtD
Raloxifene—Urethral disorder—Methotrexate—testicular cancer	0.000351	0.00152	CcSEcCtD
Raloxifene—Sinusitis—Epirubicin—testicular cancer	0.00035	0.00152	CcSEcCtD
Raloxifene—Nausea—Dactinomycin—testicular cancer	0.000348	0.00151	CcSEcCtD
Raloxifene—Pneumonia—Doxorubicin—testicular cancer	0.000347	0.0015	CcSEcCtD
Raloxifene—Gastrointestinal pain—Etoposide—testicular cancer	0.000347	0.0015	CcSEcCtD
Raloxifene—Vomiting—Ifosfamide—testicular cancer	0.000342	0.00148	CcSEcCtD
Raloxifene—Rash—Ifosfamide—testicular cancer	0.000339	0.00147	CcSEcCtD
Raloxifene—Dermatitis—Ifosfamide—testicular cancer	0.000339	0.00147	CcSEcCtD
Raloxifene—Rhinitis—Epirubicin—testicular cancer	0.000336	0.00145	CcSEcCtD
Raloxifene—Body temperature increased—Etoposide—testicular cancer	0.000336	0.00145	CcSEcCtD
Raloxifene—Abdominal pain—Etoposide—testicular cancer	0.000336	0.00145	CcSEcCtD
Raloxifene—Conjunctivitis—Doxorubicin—testicular cancer	0.000336	0.00145	CcSEcCtD
Raloxifene—Urinary tract infection—Doxorubicin—testicular cancer	0.000336	0.00145	CcSEcCtD
Raloxifene—Hypoaesthesia—Epirubicin—testicular cancer	0.000333	0.00144	CcSEcCtD
Raloxifene—Pharyngitis—Epirubicin—testicular cancer	0.000332	0.00144	CcSEcCtD
Raloxifene—Cardiac disorder—Methotrexate—testicular cancer	0.000332	0.00144	CcSEcCtD
Raloxifene—Sweating—Doxorubicin—testicular cancer	0.000331	0.00143	CcSEcCtD
Raloxifene—Urinary tract disorder—Epirubicin—testicular cancer	0.000331	0.00143	CcSEcCtD
Raloxifene—Oedema peripheral—Epirubicin—testicular cancer	0.00033	0.00143	CcSEcCtD
Raloxifene—Connective tissue disorder—Epirubicin—testicular cancer	0.000329	0.00143	CcSEcCtD
Raloxifene—Urethral disorder—Epirubicin—testicular cancer	0.000328	0.00142	CcSEcCtD
Raloxifene—Angiopathy—Methotrexate—testicular cancer	0.000325	0.00141	CcSEcCtD
Raloxifene—Sinusitis—Doxorubicin—testicular cancer	0.000324	0.0014	CcSEcCtD
Raloxifene—Nausea—Ifosfamide—testicular cancer	0.000319	0.00138	CcSEcCtD
Raloxifene—Diarrhoea—Cisplatin—testicular cancer	0.000317	0.00137	CcSEcCtD
Raloxifene—Cardiac disorder—Epirubicin—testicular cancer	0.000311	0.00135	CcSEcCtD
Raloxifene—Flushing—Epirubicin—testicular cancer	0.000311	0.00135	CcSEcCtD
Raloxifene—Rhinitis—Doxorubicin—testicular cancer	0.000311	0.00135	CcSEcCtD
Raloxifene—Hypoaesthesia—Doxorubicin—testicular cancer	0.000308	0.00134	CcSEcCtD
Raloxifene—Pharyngitis—Doxorubicin—testicular cancer	0.000308	0.00133	CcSEcCtD
Raloxifene—Urinary tract disorder—Doxorubicin—testicular cancer	0.000306	0.00133	CcSEcCtD
Raloxifene—Oedema peripheral—Doxorubicin—testicular cancer	0.000305	0.00132	CcSEcCtD
Raloxifene—Connective tissue disorder—Doxorubicin—testicular cancer	0.000305	0.00132	CcSEcCtD
Raloxifene—Angiopathy—Epirubicin—testicular cancer	0.000304	0.00132	CcSEcCtD
Raloxifene—Urethral disorder—Doxorubicin—testicular cancer	0.000304	0.00132	CcSEcCtD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000302	0.017	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000296	0.0166	CbGpPWpGaD
Raloxifene—Vomiting—Cisplatin—testicular cancer	0.000295	0.00128	CcSEcCtD
Raloxifene—Rash—Cisplatin—testicular cancer	0.000292	0.00127	CcSEcCtD
Raloxifene—Dermatitis—Cisplatin—testicular cancer	0.000292	0.00126	CcSEcCtD
Raloxifene—Diarrhoea—Etoposide—testicular cancer	0.00029	0.00126	CcSEcCtD
Raloxifene—Flushing—Doxorubicin—testicular cancer	0.000288	0.00125	CcSEcCtD
Raloxifene—Cardiac disorder—Doxorubicin—testicular cancer	0.000288	0.00125	CcSEcCtD
Raloxifene—Flatulence—Epirubicin—testicular cancer	0.000287	0.00124	CcSEcCtD
Raloxifene—Angiopathy—Doxorubicin—testicular cancer	0.000281	0.00122	CcSEcCtD
Raloxifene—Dizziness—Etoposide—testicular cancer	0.000281	0.00122	CcSEcCtD
Raloxifene—Muscle spasms—Epirubicin—testicular cancer	0.00028	0.00121	CcSEcCtD
Raloxifene—Vertigo—Methotrexate—testicular cancer	0.00028	0.00121	CcSEcCtD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000276	0.0155	CbGpPWpGaD
Raloxifene—Nausea—Cisplatin—testicular cancer	0.000275	0.00119	CcSEcCtD
Raloxifene—Cough—Methotrexate—testicular cancer	0.000272	0.00118	CcSEcCtD
Raloxifene—Vomiting—Etoposide—testicular cancer	0.00027	0.00117	CcSEcCtD
Raloxifene—Rash—Etoposide—testicular cancer	0.000268	0.00116	CcSEcCtD
Raloxifene—Dermatitis—Etoposide—testicular cancer	0.000267	0.00116	CcSEcCtD
Raloxifene—Headache—Etoposide—testicular cancer	0.000266	0.00115	CcSEcCtD
Raloxifene—Flatulence—Doxorubicin—testicular cancer	0.000266	0.00115	CcSEcCtD
Raloxifene—Arthralgia—Methotrexate—testicular cancer	0.000265	0.00115	CcSEcCtD
Raloxifene—Myalgia—Methotrexate—testicular cancer	0.000265	0.00115	CcSEcCtD
Raloxifene—Chest pain—Methotrexate—testicular cancer	0.000265	0.00115	CcSEcCtD
Raloxifene—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000265	0.0149	CbGpPWpGaD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000263	0.00114	CcSEcCtD
Raloxifene—Vertigo—Epirubicin—testicular cancer	0.000262	0.00113	CcSEcCtD
Raloxifene—Syncope—Epirubicin—testicular cancer	0.000261	0.00113	CcSEcCtD
Raloxifene—Muscle spasms—Doxorubicin—testicular cancer	0.000259	0.00112	CcSEcCtD
Raloxifene—Loss of consciousness—Epirubicin—testicular cancer	0.000256	0.00111	CcSEcCtD
Raloxifene—Cough—Epirubicin—testicular cancer	0.000254	0.0011	CcSEcCtD
Raloxifene—Infection—Methotrexate—testicular cancer	0.000253	0.00109	CcSEcCtD
Raloxifene—Nausea—Etoposide—testicular cancer	0.000252	0.00109	CcSEcCtD
Raloxifene—Nervous system disorder—Methotrexate—testicular cancer	0.000249	0.00108	CcSEcCtD
Raloxifene—Thrombocytopenia—Methotrexate—testicular cancer	0.000249	0.00108	CcSEcCtD
Raloxifene—Myalgia—Epirubicin—testicular cancer	0.000248	0.00107	CcSEcCtD
Raloxifene—Chest pain—Epirubicin—testicular cancer	0.000248	0.00107	CcSEcCtD
Raloxifene—Arthralgia—Epirubicin—testicular cancer	0.000248	0.00107	CcSEcCtD
Raloxifene—Skin disorder—Methotrexate—testicular cancer	0.000247	0.00107	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000247	0.00107	CcSEcCtD
Raloxifene—Hyperhidrosis—Methotrexate—testicular cancer	0.000246	0.00106	CcSEcCtD
Raloxifene—EBP—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000243	0.0137	CbGpPWpGaD
Raloxifene—Vertigo—Doxorubicin—testicular cancer	0.000242	0.00105	CcSEcCtD
Raloxifene—Syncope—Doxorubicin—testicular cancer	0.000242	0.00105	CcSEcCtD
Raloxifene—Loss of consciousness—Doxorubicin—testicular cancer	0.000237	0.00103	CcSEcCtD
Raloxifene—Infection—Epirubicin—testicular cancer	0.000236	0.00102	CcSEcCtD
Raloxifene—Cough—Doxorubicin—testicular cancer	0.000235	0.00102	CcSEcCtD
Raloxifene—Shock—Epirubicin—testicular cancer	0.000234	0.00101	CcSEcCtD
Raloxifene—Nervous system disorder—Epirubicin—testicular cancer	0.000233	0.00101	CcSEcCtD
Raloxifene—Thrombocytopenia—Epirubicin—testicular cancer	0.000233	0.00101	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000232	0.001	CcSEcCtD
Raloxifene—Skin disorder—Epirubicin—testicular cancer	0.000231	0.001	CcSEcCtD
Raloxifene—Hyperhidrosis—Epirubicin—testicular cancer	0.00023	0.000996	CcSEcCtD
Raloxifene—Insomnia—Methotrexate—testicular cancer	0.00023	0.000996	CcSEcCtD
Raloxifene—HTR6—GPCR ligand binding—INSL3—testicular cancer	0.00023	0.0129	CbGpPWpGaD
Raloxifene—Myalgia—Doxorubicin—testicular cancer	0.00023	0.000995	CcSEcCtD
Raloxifene—Chest pain—Doxorubicin—testicular cancer	0.00023	0.000995	CcSEcCtD
Raloxifene—Arthralgia—Doxorubicin—testicular cancer	0.00023	0.000995	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000228	0.000988	CcSEcCtD
Raloxifene—Dyspepsia—Methotrexate—testicular cancer	0.000224	0.000969	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00022	0.000951	CcSEcCtD
Raloxifene—Infection—Doxorubicin—testicular cancer	0.000219	0.000947	CcSEcCtD
Raloxifene—Pain—Methotrexate—testicular cancer	0.000217	0.000942	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000217	0.000939	CcSEcCtD
Raloxifene—Shock—Doxorubicin—testicular cancer	0.000217	0.000938	CcSEcCtD
Raloxifene—Nervous system disorder—Doxorubicin—testicular cancer	0.000216	0.000935	CcSEcCtD
Raloxifene—Thrombocytopenia—Doxorubicin—testicular cancer	0.000216	0.000934	CcSEcCtD
Raloxifene—Insomnia—Epirubicin—testicular cancer	0.000215	0.000932	CcSEcCtD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000215	0.0121	CbGpPWpGaD
Raloxifene—Skin disorder—Doxorubicin—testicular cancer	0.000214	0.000926	CcSEcCtD
Raloxifene—Hyperhidrosis—Doxorubicin—testicular cancer	0.000213	0.000922	CcSEcCtD
Raloxifene—HTR2B—GPCR ligand binding—INSL3—testicular cancer	0.00021	0.0118	CbGpPWpGaD
Raloxifene—Dyspepsia—Epirubicin—testicular cancer	0.000209	0.000907	CcSEcCtD
Raloxifene—Gastrointestinal pain—Methotrexate—testicular cancer	0.000208	0.0009	CcSEcCtD
Raloxifene—ESR1—Plasma membrane estrogen receptor signaling—MMP2—testicular cancer	0.000208	0.0117	CbGpPWpGaD
Raloxifene—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000205	0.00089	CcSEcCtD
Raloxifene—ESR1—FOXM1 transcription factor network—MMP2—testicular cancer	0.000204	0.0115	CbGpPWpGaD
Raloxifene—Pain—Epirubicin—testicular cancer	0.000203	0.000881	CcSEcCtD
Raloxifene—Body temperature increased—Methotrexate—testicular cancer	0.000201	0.00087	CcSEcCtD
Raloxifene—Abdominal pain—Methotrexate—testicular cancer	0.000201	0.00087	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000201	0.000869	CcSEcCtD
Raloxifene—Insomnia—Doxorubicin—testicular cancer	0.000199	0.000862	CcSEcCtD
Raloxifene—Gastrointestinal pain—Epirubicin—testicular cancer	0.000195	0.000843	CcSEcCtD
Raloxifene—Dyspepsia—Doxorubicin—testicular cancer	0.000194	0.000839	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.00019	0.000823	CcSEcCtD
Raloxifene—Pain—Doxorubicin—testicular cancer	0.000188	0.000815	CcSEcCtD
Raloxifene—Abdominal pain—Epirubicin—testicular cancer	0.000188	0.000815	CcSEcCtD
Raloxifene—Body temperature increased—Epirubicin—testicular cancer	0.000188	0.000815	CcSEcCtD
Raloxifene—CYP19A1—Biological oxidations—HPGDS—testicular cancer	0.000181	0.0102	CbGpPWpGaD
Raloxifene—Gastrointestinal pain—Doxorubicin—testicular cancer	0.00018	0.00078	CcSEcCtD
Raloxifene—Body temperature increased—Doxorubicin—testicular cancer	0.000174	0.000754	CcSEcCtD
Raloxifene—Abdominal pain—Doxorubicin—testicular cancer	0.000174	0.000754	CcSEcCtD
Raloxifene—Diarrhoea—Methotrexate—testicular cancer	0.000174	0.000753	CcSEcCtD
Raloxifene—Dizziness—Methotrexate—testicular cancer	0.000168	0.000728	CcSEcCtD
Raloxifene—Diarrhoea—Epirubicin—testicular cancer	0.000163	0.000705	CcSEcCtD
Raloxifene—Vomiting—Methotrexate—testicular cancer	0.000162	0.0007	CcSEcCtD
Raloxifene—Rash—Methotrexate—testicular cancer	0.00016	0.000694	CcSEcCtD
Raloxifene—Dermatitis—Methotrexate—testicular cancer	0.00016	0.000694	CcSEcCtD
Raloxifene—Headache—Methotrexate—testicular cancer	0.000159	0.00069	CcSEcCtD
Raloxifene—Dizziness—Epirubicin—testicular cancer	0.000157	0.000681	CcSEcCtD
Raloxifene—ESR1—ATF-2 transcription factor network—MMP2—testicular cancer	0.000155	0.00873	CbGpPWpGaD
Raloxifene—Vomiting—Epirubicin—testicular cancer	0.000151	0.000655	CcSEcCtD
Raloxifene—Nausea—Methotrexate—testicular cancer	0.000151	0.000654	CcSEcCtD
Raloxifene—Diarrhoea—Doxorubicin—testicular cancer	0.000151	0.000652	CcSEcCtD
Raloxifene—Rash—Epirubicin—testicular cancer	0.00015	0.00065	CcSEcCtD
Raloxifene—Dermatitis—Epirubicin—testicular cancer	0.00015	0.000649	CcSEcCtD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000149	0.00839	CbGpPWpGaD
Raloxifene—Headache—Epirubicin—testicular cancer	0.000149	0.000646	CcSEcCtD
Raloxifene—ESR2—Gene Expression—DNMT3L—testicular cancer	0.000148	0.00831	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.000146	0.00821	CbGpPWpGaD
Raloxifene—Dizziness—Doxorubicin—testicular cancer	0.000146	0.000631	CcSEcCtD
Raloxifene—Nausea—Epirubicin—testicular cancer	0.000141	0.000612	CcSEcCtD
Raloxifene—Vomiting—Doxorubicin—testicular cancer	0.00014	0.000606	CcSEcCtD
Raloxifene—Rash—Doxorubicin—testicular cancer	0.000139	0.000601	CcSEcCtD
Raloxifene—Dermatitis—Doxorubicin—testicular cancer	0.000139	0.000601	CcSEcCtD
Raloxifene—Headache—Doxorubicin—testicular cancer	0.000138	0.000597	CcSEcCtD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.000131	0.00735	CbGpPWpGaD
Raloxifene—Nausea—Doxorubicin—testicular cancer	0.000131	0.000566	CcSEcCtD
Raloxifene—HTR6—GPCR downstream signaling—INSL3—testicular cancer	0.00013	0.0073	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—KITLG—testicular cancer	0.00012	0.00677	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—INSL3—testicular cancer	0.000119	0.00666	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—INSL3—testicular cancer	0.000118	0.00663	CbGpPWpGaD
Raloxifene—CYP2B6—Biological oxidations—HPGDS—testicular cancer	0.000116	0.00654	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000108	0.00609	CbGpPWpGaD
Raloxifene—EBP—Metabolism—HPGDS—testicular cancer	0.000108	0.00608	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—INSL3—testicular cancer	0.000108	0.00605	CbGpPWpGaD
Raloxifene—CYP2C8—Biological oxidations—HPGDS—testicular cancer	9.86e-05	0.00554	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—FGFR3—testicular cancer	8.96e-05	0.00503	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—KIT—testicular cancer	8.22e-05	0.00462	CbGpPWpGaD
Raloxifene—EBP—Metabolism—STK11—testicular cancer	7.86e-05	0.00442	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—DNMT3L—testicular cancer	7.46e-05	0.00419	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—INSL3—testicular cancer	6.97e-05	0.00392	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	6.96e-05	0.00391	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—INSL3—testicular cancer	6.36e-05	0.00357	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—HPGDS—testicular cancer	6e-05	0.00337	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—INSL3—testicular cancer	5.3e-05	0.00298	CbGpPWpGaD
Raloxifene—CYP3A4—Biological oxidations—HPGDS—testicular cancer	5.29e-05	0.00297	CbGpPWpGaD
Raloxifene—AOX1—Disease—H2AFZ—testicular cancer	5.23e-05	0.00294	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—H2AFZ—testicular cancer	5.17e-05	0.00291	CbGpPWpGaD
Raloxifene—AOX1—Disease—KITLG—testicular cancer	4.81e-05	0.0027	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—STK11—testicular cancer	4.36e-05	0.00245	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.79e-05	0.00213	CbGpPWpGaD
Raloxifene—AOX1—Disease—FGFR3—testicular cancer	3.58e-05	0.00201	CbGpPWpGaD
Raloxifene—AOX1—Disease—KIT—testicular cancer	3.29e-05	0.00185	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—HPGDS—testicular cancer	3.1e-05	0.00174	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—H2AFZ—testicular cancer	2.61e-05	0.00147	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—STK11—testicular cancer	2.25e-05	0.00127	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—H2AFZ—testicular cancer	2.23e-05	0.00125	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—STK11—testicular cancer	2.22e-05	0.00125	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KITLG—testicular cancer	2.05e-05	0.00115	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—H2AFZ—testicular cancer	2.04e-05	0.00114	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—STK11—testicular cancer	2.02e-05	0.00114	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—HPGDS—testicular cancer	1.99e-05	0.00112	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KITLG—testicular cancer	1.87e-05	0.00105	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—H2AFZ—testicular cancer	1.7e-05	0.000953	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—STK11—testicular cancer	1.69e-05	0.000948	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—HPGDS—testicular cancer	1.69e-05	0.000947	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KITLG—testicular cancer	1.56e-05	0.000877	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—FGFR3—testicular cancer	1.53e-05	0.000857	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—STK11—testicular cancer	1.45e-05	0.000813	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KIT—testicular cancer	1.4e-05	0.000787	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—FGFR3—testicular cancer	1.39e-05	0.000782	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KIT—testicular cancer	1.28e-05	0.000718	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—STK11—testicular cancer	1.23e-05	0.000688	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—FGFR3—testicular cancer	1.16e-05	0.000652	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KIT—testicular cancer	1.07e-05	0.000598	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—HPGDS—testicular cancer	9.05e-06	0.000508	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—STK11—testicular cancer	6.58e-06	0.000369	CbGpPWpGaD
